Free tool
FAERS Monitor: Bystolic
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021742 or its brand name (Bystolic, Nebivolol Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
17,999
Serious
9,157
51% of reports
Hospitalization
4,412
Death reported
861
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue1,332
- drug ineffective1,073
- diarrhoea1,060
- nausea1,030
- headache982
- dyspnoea936
- dizziness906
- off label use712
- pain660
- asthenia622
- blood pressure increased587
- arthralgia539
- malaise518
- hypertension517
- fall511
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 10 |
| 2006 | 8 |
| 2007 | 12 |
| 2008 | 77 |
| 2009 | 634 |
| 2010 | 727 |
| 2011 | 610 |
| 2012 | 821 |
| 2013 | 906 |
| 2014 | 1,056 |
| 2015 | 1,619 |
| 2016 | 1,982 |
| 2017 | 1,351 |
| 2018 | 1,643 |
| 2019 | 1,399 |
| 2020 | 1,160 |
| 2021 | 840 |
| 2022 | 917 |
| 2023 | 681 |
| 2024 | 628 |
| 2025 | 539 |
| 2026 | 373 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,036,160 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood pressure increasedSignal | 587 | 4.5 | 4.2 | 1,600 |
| hypertensionSignal | 517 | 2.9 | 2.6 | 627 |
| dizzinessSignal | 906 | 2.1 | 2.0 | 550 |
| fatigueSignal | 1,332 | 2.0 | 1.9 | 690 |
| asthenia | 622 | 1.9 | 1.8 | 285 |
| dyspnoea | 936 | 1.9 | 1.8 | 432 |
| diarrhoea | 1,060 | 1.9 | 1.8 | 481 |
| headache | 982 | 1.8 | 1.7 | 381 |
| fall | 511 | 1.8 | 1.6 | 182 |
| nausea | 1,030 | 1.5 | 1.4 | 190 |
| arthralgia | 539 | 1.5 | 1.4 | 96 |
| malaise | 518 | 1.4 | 1.3 | 55 |
| pain | 660 | 1.3 | 1.2 | 35 |
| drug ineffective | 1,073 | 1.0 | 0.9 | 3 |
| off label use | 712 | 1.0 | 0.9 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.